Investment Thesis
Substantial late stage clinical assets:
Phase 3 study for advanced lung cancer (NSCLC ... More than 100M€ raised publicly with approved EU/US products
OSE
Pba-Th 2
EFTA01113740
OSE
Pharma
Investment Thesis
1st round to be raised: 5M€ plus commitment ... Phase 2 execution for Cystic Fibrosis (amucoviscidose» a genetic disorder)
OSE
Pba 3
EFTA01113741
OSE
Pharma
Market opportunity : €1.4B
OSE
2101 targeted cancer immune therapy:
EUROPE HLA A2 positive